Study finds NJoy e-cigarette use can help short-term smoking reduction and cessation potential
SCOTTSDALE, Ariz. — NJoy today announced the results of a pilot study that has been accepted for publication in the American Journal of Health Behavior and will be published online on October 1, 2013. The study, supported by NJoy and led by independent researchers Mitchell Nides, Ph.D. and Scott Leischow, Ph.D. evaluated nicotine delivery from the NJoy Kings Bold Electronic Delivery System (ENDS) and its short-term potential for smoking reduction or cessation. Results indicated that the NJoy Kings Bold ENDS delivered nicotine at a rate comparable to some FDA-approved nicotine replacement therapy products and that use of the product during the course of the one-week study led to short-term smoking reduction.
The open-label study, consisting of 25 smokers ages 18 years to 65 years who were not interested in quitting, found:
- Mean daily cigarette smoking decreased from the baseline week to the trial week in 89% of subjects, with a statistically significant mean reduction in cigarettes smoked per day of 39%.
- Smoking was reduced by 50% or more in 32% of subjects.
- 16% of subjects had reduced their consumption of cigarettes to zero by the end of the study period.
- Subjects had generally favorable perceptions of the NJoy Kings product at the end of the one-week trial period, with more than half reporting “high satisfaction” with a number of product features.
The results suggest that the NJoy Kings product delivered enough nicotine to suppress craving and was generally liked. However, the small number of subjects and short one-week testing period limit the study’s efficacy. Thus, while the results indicated that the NJoy Kings product has potential for use in smoking reduction and cessation, larger trials are needed.
“NJoy is actively engaged in expanding the science base on the health effects of electronic cigarettes and their potential to reduce the harms associated with traditional tobacco cigarettes,” said Dr. Richard Carmona, former Surgeon General of the United States and the chair of NJoy’s Scientific Advisory Committee. “These preliminary findings underscore the need for further research on the category and its potential for harm reduction.”
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.